Accure

Accure Therapeutics is a private translational neuroscience biopharma company focused on developing disease-modifying medicines for central nervous system disorders. Based in Barcelona, the company builds and advances a pipeline of primarily small-molecule neuroprotective and neurorepair programs targeting indications including acute optic neuritis, glaucoma, Parkinson's disease, multiple sclerosis, and epilepsy. Its lead asset, ACT-01, reached Phase 2 in acute optic neuritis and was licensed to Oculis, while ACT-02 for Parkinson's disease is in advanced preclinical development and ACT-03 is being evaluated for post-traumatic epilepsy. The company positions itself as an R&D engine designed to mature CNS assets through translational development and partnership-driven value creation.